Vulval cancer Flashcards Preview

Gynae oncology > Vulval cancer > Flashcards

Flashcards in Vulval cancer Deck (29)
Loading flashcards...
1

What proportion of gynaecological cancer does vulval cancer account for?

2-5%

2

Most common type of vulval cancer?

SCC

3

Risk factors for vulval cancer

- Postmenopausal
- HPV infection
-smoking
- HIV
- Lichen sclerosis

4

Lymphatic drainage of the vulva

- Primarily to inguinofemoral region
- Secondarily to external and internal iliac nodes

- Cancer can have unilateral or bilateral spread

5

Which other areas also share lymphatic drainage with the vulva?

inferior third of the vaginal tube and the most external portion of the anus (below the anal sphincter)

6

Primary prevention of vulval cancer

HPV vaccination (HPV 16 most common subtype causing HSIL and SCC)

7

Secondary prevention of vulval cancer

- No screening
- Self examination if they have lichen sclerosis
- women who are known to have squamous intraepithelial lesion (SIL) of the cervix, vagina, or anus should have inspection of the vulva as part of their follow‐up colposcopy visits
- Women with signs or symptoms of vulval cancer should have early biopsy

8

Two main pathological pathways that lead to vulvar SCC

1. Keratinizing SCC usually occurs in older women and is often associated with lichen sclerosus and/or differentiated vulvar intraepithelial neoplasia (dVIN).

2. Warty/basaloid SCC
- occurs in younger women,
- persistent infection with oncogenic strains of HPV (particularly HPV 16, 18, 31 and 33),
- has SIL as its precursor lesion.
- Lesions are frequently multifocal,
- HIV infection and cigarette smoking are also common predisposing factors

9

3 subtypes of premalignant lesions of the vulva

- low‐grade squamous intraepithelial lesions (LSIL);
- high‐grade squamous intraepithelial lesions (HSIL);
- differentiated VIN

10

Treatment of dVIN

- More likely to become malignancy than HSIL/LSIL
- Less likely to be associated with HPV
- Faster progression

Therefore- recommend surgical excision with 5‐mm margins and 4‐mm depth

Non surgical options: (reduce psychosexual morbidity)
- Diathermy
- Imiquimod
Disadvantage- can't assess for occult invasion

11

FIGO stage:
1
1A
1B

1. Tumor confined to the vulva
IA Lesions ≤2 cm in size, confined to the vulva or perineum and with stromal invasion ≤1.0 mm, no nodal metastasis
IB Lesions >2 cm in size or with stromal invasion >1.0 mm, confined to the vulva or perineum, with negative nodes

12

FIGO stage 2

Tumor of any size with extension to adjacent perineal structures (lower third of urethra, lower third of vagina, anus) with negative nodes

13

FIGO stage 3
3A
3B
3C

3: Tumor of any size with or without extension to adjacent perineal structures (lower third of urethra, lower third of vagina, anus) with positive inguinofemoral nodes

IIIA With 1 lymph node metastasis (≥5 mm), or
With 1–2 lymph node metastasis(es) (<5 mm)

IIIB With 2 or more lymph node metastases (≥5 mm), or
With 3 or more lymph node metastases (<5 mm)

IIIC With positive nodes with extracapsular spread

14

FIGO stage 4
4A
4B

4: Tumor invades other regional (upper 2/3 urethra, upper 2/3 vagina), or distant structures

IVA Tumor invades any of the following:
upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, or fixed to pelvic bone, or
fixed or ulcerated inguinofemoral lymph nodes

IVB Any distant metastasis including pelvic lymph nodes

15

6 histopathological types of vulvar cancer

Squamous cell carcinoma (80%)
Basal cell carcinoma
Verrucous carcinoma
Paget's disease of the vulva
Adenocarcinoma, not otherwise specified
Bartholin gland carcinoma

16

Grade of vulvar cancer

GX: Grade cannot be assessed
G1: Well differentiated
G2: Moderately differentiated
G3: Poorly or undifferentiated

17

Principles of treatment

- Depends primarily on histology and staging.
- Other variables: age, coexistence of comorbidities, and performance status of the patient.

Treatment is predominantly surgical, particularly for SCC.

Concurrent chemoradiation is an effective alternative, for advanced tumors, and those where exenteration would be necessary to achieve adequate surgical margins.

Management should be individualized, and carried out by a MDT in a cancer center

Other therapies such as chemotherapy and immunotherapies are usually reserved for metastatic or palliative settings, or for the treatment of rare histologies such as melanoma

18

Symptoms of vulvar cancer

- May be asymptomatic,
- vulvar pruritus or pain,
-Lump or ulcer
-abnormal bleeding or discharge
-May have underlying lichen sclerosus or HSIL.
- Advanced vulvar cancer may present with a lump in the groin due to lymph node metastases.

19

Diagnosis

Vulvar biopsy- try not to excise whole lesion if small as make subsequent surgery harder

20

Who is suitable for WLE?

Stage 1A:
- Lesion <2cm
- Depth of stromal invasion < 1mm

Groin node dissection not necessary

WLE as effective as vulvectomy but has less psychosocial morbidity

Aim for surgical margins of 2cm (pathological of 8mm)

21

Investigations

1. Cervical cytology, and colposcopy of the cervix and vagina, due to the association of HPV‐related cancers with other squamous intraepithelial lesions.

2. Full blood count, biochemical profile, liver profile, and HIV testing.

3. Chest X‐ray.

4. CT or MRI scan of the pelvis and groin

5. 18F‐FDG PET‐CT can more effectively assess and detect inguinofemoral lymph node involvement compared with CT, influencing the planning of primary surgery and inguinal lymph node dissection to determine the optimum surgical extent without sentinel lymph node dissection and use of frozen sections. Additionally, PET‐CT might be used with larger tumors when metastatic disease is suspected or in the recurrence scenario.

22

Management: stage 1b or 2

All women who have Stage IB or Stage II cancers should have an inguinofemoral lymphadenectomy.

23

Management of small lateral lesions (less than 4 cm and ≥2 cm from the vulvar midline)

Ipsilateral groin dissection as <1% will have contralateral groin nodes

24

Management if
- tumor closer to (<2 cm) or crossing the midline,
- very large lateral tumors (>4 cm),
- positive ipsilateral nodes

bilateral groin node dissection

25

Indications for a sentinel node procedure, as per the GROINSS‐V study

Unifocal tumors confined to the vulva
Tumors less than 4 cm in diameter
Stromal invasion more than 1 mm
Clinically negative groin nodes

26

How are sentinel nodes detected?

Sentinel lymph nodes are identified using both radio‐labelled technetium and blue dye

27

indications for pelvic and groin irradiation in patients with positive groin nodes are:

Presence of extracapsular spread.
Two or more positive groin nodes

Target inguinofemoral and external and internal iliac lymph nodes with ERBT. Brachytherapy can also be used some times.

28

Management of advanced vulvar cancer

- Identify nodal involvement pre-op with FNA and PET-CT/MRI or CT
- No nodes identified- perform blateral lymphadenectomy. If no nodes positive then radiotherapy to nodes not necessary.
- If patient has multiple comorbidities/surgery inappropriate then primary chemoradiation may be used to treat the primary tumor as well as the groin and pelvic nodes
- surgical excision of the primary tumor with clear surgical margins and without sphincter damage, whenever possible.

29

Indication for chemoradiation

- If adequate excision of the primary tumor can only be achieved by exenteration and the formation of a bowel or urinary stoma, radiotherapy (with or without concurrent chemotherapy) may be a preferred treatment alternative. Survival is improved if any postradiation residual tumor is resected

- If patient has multiple comorbidities/surgery inappropriate then primary chemoradiation may be used to treat the primary tumor as well as the groin and pelvic nodes

- Chemotherapy agents: cisplatin and 5‐fluorouracil